IL160105A0 - Vaccine for treatment of motor neurone diseases - Google Patents

Vaccine for treatment of motor neurone diseases

Info

Publication number
IL160105A0
IL160105A0 IL16010502A IL16010502A IL160105A0 IL 160105 A0 IL160105 A0 IL 160105A0 IL 16010502 A IL16010502 A IL 16010502A IL 16010502 A IL16010502 A IL 16010502A IL 160105 A0 IL160105 A0 IL 160105A0
Authority
IL
Israel
Prior art keywords
cop
vaccine
treatment
motor neurone
tyr
Prior art date
Application number
IL16010502A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IL160105A0 publication Critical patent/IL160105A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL16010502A 2001-12-06 2002-12-05 Vaccine for treatment of motor neurone diseases IL160105A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en) 2001-12-06 2002-12-05 Vaccine and method for treatment of motor neurone diseases

Publications (1)

Publication Number Publication Date
IL160105A0 true IL160105A0 (en) 2004-06-20

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16010502A IL160105A0 (en) 2001-12-06 2002-12-05 Vaccine for treatment of motor neurone diseases

Country Status (24)

Country Link
US (1) US7351686B2 (xx)
EP (1) EP1429800B1 (xx)
JP (1) JP4542339B2 (xx)
KR (1) KR20040081431A (xx)
CN (2) CN102151330B (xx)
AT (1) ATE422362T1 (xx)
AU (1) AU2002353486B2 (xx)
CA (1) CA2469092C (xx)
CY (1) CY1109044T1 (xx)
DE (1) DE60231131D1 (xx)
DK (1) DK1429800T3 (xx)
ES (1) ES2322566T3 (xx)
HK (1) HK1067043A1 (xx)
HU (1) HU228207B1 (xx)
IL (1) IL160105A0 (xx)
IS (1) IS2670B (xx)
MX (1) MXPA04005537A (xx)
NO (1) NO336231B1 (xx)
NZ (1) NZ533356A (xx)
PL (1) PL205469B1 (xx)
PT (1) PT1429800E (xx)
RU (1) RU2303996C2 (xx)
SI (1) SI1429800T1 (xx)
WO (1) WO2003047500A2 (xx)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
MXPA05007329A (es) * 2003-01-07 2005-09-30 Yeda Res & Dev Vacuna de gotas oculares que contiene copolimero 1 para inmunizacion terapeutica.
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
JP4808631B2 (ja) 2003-12-09 2011-11-02 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 精神医学的障害の治療用のコポリマー１を含む方法及びワクチン
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
EP1750742A2 (en) * 2004-05-07 2007-02-14 Peptimmune, Inc. Methods of treating disease with random copolymers
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2615506A1 (en) * 2005-07-15 2007-01-25 Novartis Ag Pamps, pathogen associated molecular patterns
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
US8193147B2 (en) 2007-09-24 2012-06-05 Hadasit Medical Research Services & Development Ltd. Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2602977T3 (es) 2010-10-11 2017-02-23 Teva Pharmaceutical Industries Ltd. Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
EA201490749A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. Однонуклеотидные полиморфизмы, полезные для прогнозирования клинической реакции на глатирамера ацетат
EP2788017B1 (en) * 2011-12-05 2017-05-31 Ben-Gurion University of The Negev Research and Development Authority INHIBITORS OF IgG-A2BG2 FOR USE IN TREATING AND DIAGNOSING AMYOTROPHIC LATERAL SCLEROSIS
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
US20150238582A1 (en) 2012-09-10 2015-08-27 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
SE505316C2 (sv) 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
WO1999034827A1 (en) 1998-07-21 1999-07-15 Yeda Research And Development Co. Ltd. Activated t-cells and their uses
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20030108528A1 (en) * 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
JP2003532618A (ja) 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド 細胞、神経系−特異的抗原およびそれらの用途
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
MXPA02007106A (es) * 2000-01-20 2002-12-13 Mcinnis Patricia A El uso del copolimero 1 y peptidos y polipeptidos relacionados y celulas t tratadas con estos para terapia neuroprotectora.
NZ520282A (en) * 2000-06-07 2004-09-24 Yeda Res & Dev The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
NO20042833L (no) 2004-08-12
HUP0500039A3 (en) 2010-01-28
PL205469B1 (pl) 2010-04-30
EP1429800A4 (en) 2006-03-22
CN102151330B (zh) 2017-04-12
CN1617736A (zh) 2005-05-18
RU2004120536A (ru) 2005-03-27
CA2469092C (en) 2013-02-19
US7351686B2 (en) 2008-04-01
NO336231B1 (no) 2015-06-22
WO2003047500A3 (en) 2004-03-18
PL370070A1 (en) 2005-05-16
AU2002353486A1 (en) 2003-06-17
WO2003047500A2 (en) 2003-06-12
KR20040081431A (ko) 2004-09-21
EP1429800B1 (en) 2009-02-11
IS2670B (is) 2010-09-15
MXPA04005537A (es) 2004-11-01
AU2002353486B2 (en) 2009-01-15
ES2322566T3 (es) 2009-06-23
EP1429800A2 (en) 2004-06-23
HK1067043A1 (en) 2005-04-01
ATE422362T1 (de) 2009-02-15
CA2469092A1 (en) 2003-06-12
PT1429800E (pt) 2009-04-27
CY1109044T1 (el) 2014-07-02
SI1429800T1 (sl) 2009-08-31
DK1429800T3 (da) 2009-04-27
IS7296A (is) 2004-06-03
US20050220802A1 (en) 2005-10-06
RU2303996C2 (ru) 2007-08-10
NZ533356A (en) 2006-10-27
JP2005515198A (ja) 2005-05-26
JP4542339B2 (ja) 2010-09-15
DE60231131D1 (de) 2009-03-26
CN102151330A (zh) 2011-08-17
HU228207B1 (hu) 2013-01-28
HUP0500039A2 (hu) 2005-03-29

Similar Documents

Publication Publication Date Title
IL160105A0 (en) Vaccine for treatment of motor neurone diseases
AU6185398A (en) Charged lipids and uses for the same
EA200601132A1 (ru) Предупреждение и лечение амилоидогенного заболевания
HUP0401568A2 (hu) Periokuláris vagy subconjunctivális adagolásra alkalmas szemészeti depó készítmények
AU6762794A (en) A coagulation factor viii formulation
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
UA88270C2 (ru) Фармацевтический препарат и его применение для профилактики удара, диабета
TW200509968A (en) Prevention and treatment of synucleinopathic disease
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
HK1049444A1 (en) Transdermal therapeutic system for parkingson's disease inducing high plasma levels of rotigotine
IL110045A (en) Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides
HK1029043A1 (en) Remedy for neurodegenerative diseases.
CA2299361A1 (en) Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
AU7242796A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
HK1068606A1 (en) Novel aminobenzoephenones
MXPA02005563A (es) Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma.
CA2225788A1 (en) Therapeutic agents and autoimmune diseases
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
NZ505538A (en) A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma
YU45103A (sh) Upotreba sarp/1 za lečenje i prevenciju skleroderme
CA2414586A1 (en) Agent for therapeutic treatment of optic nerve diseases and the like
WO2003026570A3 (en) Reduced toxicity cisplatin formulations and methods for using the same
GB2407321A (en) Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor